The CRISPR Journal announces the publication of its August 2019 issue. The Journal is dedicated to validating and publishing outstanding research and commentary on all aspects of CRISPR and gene editing, including CRISPR biology, technology, and genome editing, and commentary and debate of key policy, regulatory, and ethical issues affecting the field. The Journal, led by
South Korea is seeking to ease legislative restrictions to allow research on breakthrough gene therapies using gene editing and other advanced gene correction tools. The Ministry of Health and Welfare said on Thursday it is revising the Bioethics Act to allow gene therapy research in this direction. Rep. Yoon Il-kyu of the ruling Democratic Party,
There’s hope a gene therapy being developed at the Australian National University could one day help save the eyesight of millions. The therapy is working on preventing the loss of eyesight from dry age-related macular degeneration (dry AMD). Dry AMD is a common disorder that is caused by damage to the macula – the part
Pfizer announced today an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina. This facility is anticipated to support Pfizer’s continuing investment in gene therapy research and development, similar to Pfizer’s Chapel Hill and Kit Creek, North Carolina research and development sites. This facility would
Source Transparency Market Research Gene Therapy Market – Snapshot The global gene therapy market is expanding at an exponential pace due to promising therapeutic outcomes of gene therapy, high prevalence and rise in incidence of cancer, and large number of clinical research pipeline products. In terms of revenue, the market was valued at US$ 17.0
Source Global Data Gene therapy involves the delivery of complex treatments to patients. In recent years, there have been several promising clinical trial results within this field targeting an array of inherited neurodegenerative disorders, genetic diseases, and various cancers. Approvals based on these clinical trials have consequently encouraged interest in gene therapy from both industry
Researchers at ETH Zurich have refined the famous CRISPR-Cas method. Now, for the very first time, it is possible to modify dozens, if not hundreds, of genes in a cell simultaneously. Everyone’s talking about CRISPR-Cas. This biotechnological method offers a relatively quick and easy way to manipulate single genes in cells, meaning they can be
Safety, innovation and affordability need not be mutually exclusive goals for cutting-edge treatments. Source NYT Spinal muscular atrophy is a condition often fatal by age 2. Babies with the disorder have a rare genetic mutation that prevents the nervous system from controlling certain muscles. As they grow to be toddlers, these children struggle to move their limbs,
Source https://www.liebertpub.com/doi/pdf/10.1089/hum.2019.026#utm_source=ETOC&utm_medium=email&utm_campaign=hum Corneal diseases are among the most prevalent causes of blindness worldwide. The transparency and clarity of the cornea are guaranteed by a delicate physiological, anatomic, and functional balance. For this reason, all the disorders, including those of genetic origin, that compromise this state of harmony can lead to opacity and eventually vision loss.
Source STAT A common saying at the Food and Drug Administration is: “In God we trust, all others must bring data.” The independent evaluation of science is an essential element of the FDA’s dual role of protecting the public health and promoting innovation to bring new therapies into practice. In fact, with certain exceptions, the
